Top in women’s health: Updates on hot flash treatments, postpartum hypertension

Fezolinetant performed better than other nonhormonal medications at reducing vasomotor symptoms due to menopause, according to a recent meta-analysis of randomized studies.
Marketed by Astellas as Veozah, fezolinetant is a nonhormone neurokinin 3 receptor agonist that was approved by the FDA in the first half of 2023. A 45-mg once-daily dose “was significantly more effective in reducing the frequency of moderate to severe vasomotor symptoms than available [nonhormonal therapy] options,” researchers said. “For reduction in vasomotor symptoms severity, fezolinetant 45 mg was

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart